Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

ImmuCell Corporation (ICCC) vs Pelthos Therapeutics Inc. (PTHS)

ImmuCell Corporation and Pelthos Therapeutics Inc. are both Biotechnology companies. ImmuCell Corporation and Pelthos Therapeutics Inc. are of similar size ($90.6M and $85.8M). Pelthos Therapeutics Inc. has negative trailing earnings, so its P/E is not meaningful; ImmuCell Corporation trades at 117×. ImmuCell Corporation has the higher net margin (2.57% vs −199.5%) and the higher return on invested capital (7.84% vs −82.3%). Across the 15 metrics below, ImmuCell Corporation leads on 10 and Pelthos Therapeutics Inc. on 5.

Valuation

Metric ICCC PTHS Biotechnology median
P/E 117.38 n/m 7.88
P/S 2.93 1.82 11.47
P/B 2.87 n/m 2.52
Price to free cash flow 21.27 n/m 21.16
EV/EBITDA 14.22 n/m 0.74
EV/Sales 2.92 2.92 10.73
Earnings yield 0.85% (128.97%) (28.84%)
Free cash flow yield 4.70% (54.04%) (23.03%)

Profitability

Metric ICCC PTHS Biotechnology median
Gross margin 40.32% 78.59% 65.16%
Operating margin 12.60% (133.42%) 0.00%
Net margin 2.57% (199.50%) 0.00%
Free cash flow margin 13.79% (98.37%) 0.00%
Return on equity 2.57% 2,161.07% (57.72%)
Return on assets 1.69% (125.04%) (49.22%)
Return on invested capital 7.84% (82.34%) 0.00%

Growth

Metric ICCC PTHS Biotechnology median
Revenue growth (TTM) 8.49% — 5.64%
EPS growth (last fiscal year) 53.85% (61.12%) —
Revenue growth, 5-year CAGR 12.50% — 8.40%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric ICCC PTHS Biotechnology median
Debt to equity 0.26 (46.58) 0.00
Current ratio 4.75 1.98 4.73
Net debt to EBITDA 1.19 (0.45) 0.96

Dividend

Metric ICCC PTHS Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric ICCC PTHS Biotechnology median
Market cap 90.55m 85.76m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack